A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT04985136 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor R \& D Strategy Adjustment

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG: camrelizumab；Rivoceranib
DRUG: Rivoceranib
DRUG: Sorafenib
DRUG: Regorafenib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.